Yüklüyor......

The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials

As the drug development pipeline for Duchenne muscular dystrophy (DMD) rapidly advances, clinical trial outcomes need to be optimized. Effective assessment of disease burden, natural history progression, and response to therapy in clinical trials for Duchenne muscular dystrophy are critical factors...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Neurotherapeutics
Asıl Yazarlar: Chrzanowski, Stephen M., Darras, Basil T., Rutkove, Seward B.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2019
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007477/
https://ncbi.nlm.nih.gov/pubmed/31879850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-019-00825-1
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!